Novo Nordisk A/S - Share repurchase programme
On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.
Since the announcement as of 8 February 2010, the following transactions have been made under the programme:
Number of shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 435,000 | 162,272,753 | |
08 February 2010 | 90,000 | 373.8999 | 33,650,991 |
09 February 2010 | 90,000 | 374.0000 | 33,660,000 |
10 February 2010 | 90,000 | 374.0290 | 33,662,610 |
11 February 2010 | 90,000 | 378.7490 | 34,087,410 |
12 February 2010 | 90,000 | 385.0110 | 34,650,990 |
Accumulated under the programme | 885,000 |
| 331,984,754 |
Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010 to 12 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 31,281,948 treasury shares, corresponding to 5.0% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
Media: | Investors: |
Elin K Hansen | Klaus Bülow Davidsen |
Tel: (+45) 4442 3450 | Tel: (+45) 4442 3176 |
Kasper Roseeuw Poulsen | |
Tel: (+45) 4442 4471 | |
In North America: | In North America: |
Sean Clements | Hans Rommer |
Tel: (+1) 609 514 8316 | Tel: (+1) 609 919 7937 |
Company Announcement no 9 / 2010